LLY
Lilly’s got the credit card out
Eli Lilly is spending big again. The company said it will acquire Centessa in a deal that values the target at roughly $6.3 billion upfront, with up to $1.5 billion more tied to contingent value rights. That’s not exactly couch-cushion change.
The headline number is the kind that makes investors squint twice. Lilly’s offering $38 per share, which it says is more than a 40% premium to Centessa’s 30-day volume-weighted average price before the deal was announced. Translation: Centessa holders are getting a fat check, and Lilly is paying up for a shot at future pipeline upside.
Why this matters for your stock watch
This is classic pharma chess: spend now, hope the science pays off later. Lilly’s already one of the market’s most closely watched drugmakers, and this deal suggests it’s still willing to deploy a mountain of capital to defend its growth story.
A few things to keep on your radar:
- both boards have approved the acquisition
- the deal still needs regulatory approval and sign-off from Centessa investors
- Lilly and Centessa expect it could close as soon as Q3 this year
The bigger Lilly plotline
The timing is spicy. Lilly has been dealing with fresh regulatory headaches around its obesity franchise, but that hasn’t stopped it from shopping. If this acquisition lands, it could give Lilly more firepower in a pipeline race where the winners are often the companies with the deepest pockets and the best late-stage bets.
Big picture: Lilly isn’t acting like a company playing defense. It’s acting like one that wants to keep buying the next chapter before a rival does.